Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD-1 knockout antigen-specific TCR-T cells
- Development stage
- Preclinical
- Lead developer
- Shenzhen Inno Immune
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
PD-1 knockout antigen-specific TCR-T cells is a gene-edited T-cell receptor-engineered T-cell (TCR-T) therapy being developed by Shenzhen Innovation Immunotechnology for the treatment of melanoma. The therapy involves engineering T cells to express a specific T-cell receptor (TCR) targeting tumor antigens, combined with the CRISPR-mediated knockout of the programmed cell death protein 1 (PD-1) gene. By removing PD-1, the T cells are rendered resistant to PD-L1-mediated immunosuppression within the tumor microenvironment, potentially enhancing their persistence, functional activity, and tumor-killing capacity. The program is currently in the preclinical stage of development.
- Other names
- PD-1 knockout T-cell receptor-engineered T cellsPD1 knockout T-cell receptor-engineered T cellsPD 1 knockout T-cell receptor-engineered T cells
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)pMHC-II (Peptide-major histocompatibility complex class II complex)
Beyond the preview
Go deeper on PD-1 knockout antigen-specific TCR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PD-1 knockout antigen-specific TCR-T cells.